Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NXE4
UPID:
NSMA3_HUMAN
Alternative names:
Neutral sphingomyelinase 3; Neutral sphingomyelinase III
Alternative UPACC:
Q9NXE4; B1PBA3; B4DM23; B4DQ31; B4DRB8; B4DWK7; B4E0L6; E7ESA2; E9PCE6; Q6FI76; Q6P1P7; Q6ZT43; Q9H0M2; Q9NW20; Q9NWL2; Q9P2C9
Background:
Sphingomyelin phosphodiesterase 4, also known as Neutral sphingomyelinase 3, plays a crucial role in the hydrolysis of membrane sphingomyelin, producing phosphorylcholine and ceramide. This process is vital for maintaining membrane sphingolipid homeostasis, membrane integrity, and proper endoplasmic reticulum organization. Additionally, it contributes to cell sensitivity to DNA damage-induced apoptosis and mediates TNF-stimulated oxidant production in skeletal muscle.
Therapeutic significance:
Given its involvement in Neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, targeting Sphingomyelin phosphodiesterase 4 could offer a novel approach for therapeutic intervention in this severe condition. Understanding the role of this protein could open doors to potential therapeutic strategies.